Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab

BACKGROUND: BCD-022 is a trastuzumab biosimilar which was shown to be equivalent to reference trastuzumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to comparatively assess efficacy...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:BMC Cancer
मुख्य लेखकों: Alexeev, Sergey M., Khorinko, Andrey V., Mukhametshina, Guzel Z., Shelepen, Konstantin G., Burdaeva, Olga N., Kulik, Sergey A., Satheesh, Chiradoni Thugappa, Srivastava, Kirti, Vikranth, Mummaneni, Kryukov, Fedor, Paltusova, Anastasia N., Shustova, Mariya S., Ivanov, Roman A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2020
विषय:
Research Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7439710/
https://ncbi.nlm.nih.gov/pubmed/32819305
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07247-9
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन